Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

Prostate

Volumn 72, Issue 8, 2012, Pages 856-867

  Henry, J Y ^a   Lu, L ^b   Adams, M ^b   Meyer, B ^a   Bartlett, J B ^b   Dalgleish, A G ^a   Galustian, C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

Author keywords

apoptosis; CRPC; docetaxel; lenalidomide; p53; prostate

Indexed keywords

DOCETAXEL; LENALIDOMIDE; PROTEIN BAD; PROTEIN P53; PROTEIN P58;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; TAXOIDS; THALIDOMIDE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860348682     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21488     Document Type: Article

References (42)

1. Chowdhury S, Burbridge S, Harper PG,. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 2007; 61: 2064-2070. (Pubitemid 350077400)
2. Anast JW, Andriole GL, Grubb RL,. Managing the local complications of locally advanced prostate cancer. Curr Urol Rep 2007; 8: 211-216. (Pubitemid 46806650)
3. Tannock IF, de Wilt R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
4. Mackler NJ, Pienta KJ,. Drug insight: Use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2005; 2: 92-100. (Pubitemid 40790129)
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
6. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG,. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 2004; 4: 1963-1970. (Pubitemid 39627147)
7. Bartlett JB, Dredge K, Dalgleish AG,. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322. (Pubitemid 38525287)
8. Grant DS, Williams TL, Zahaczewsky M, Dicker AP,. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104: 121-129. (Pubitemid 36184155)
9. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL,. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): Association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002; 1: 1191-1200.
10. Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM,. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 2009; 27: 453-460.
11. Moss RA, Mohile SG, Shelton G, Melia J, Petrylak DP,. A phase I open-label study using lenalidomide and docetaxel in androgen independent prostate cancer (AIPC), Meeting: 2007 Prostate Cancer Symposium, Abstract No: 89.
12. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD,. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142. (Pubitemid 350146108)
13. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San MJ, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD,. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
14. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R,. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. (Pubitemid 44511560)
15. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI,. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849-858. (Pubitemid 43816707)
16. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de PL, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW,. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755. (Pubitemid 46192215)
17. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC,. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002; 99: 4525-4530. (Pubitemid 34627223)
18. Galustian C, Dalgleish A,. Lenalidomide: A novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009; 10: 125-133.
19. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D,. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.
20. Dalgleish AG, Bartlett JB, Galustian C, Fryer RA,. Molecular mechanisms underlying gemcitabine resistance in pancreatic cancer and restoration of sensitivity using lenalidomide. J Clin Oncol (Meeting Abstracts) 28: e13630.
21. Wu L, Liu W, Galustian C, Schafer P, Dalgleish AG, Bartlett JB,. Effect of lenalidomide on the antiproliferative effect of gemcitabine against pancreatic tumor cells and on immune-mediated pancreatic cancer cell death. J Clin Oncol (Meeting Abstracts) 2009; 27: e14635.
22. Ozono S, Miyao N, Igarashi T, Marumo K, Nakazawa H, Fukuda M, Tsushima T, Tokuda N, Kawamura J, Murai M,. Tumor doubling time of renal cell carcinoma measured by CT: Collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol 2004; 34: 82-85. (Pubitemid 43115324)
23. Liu WM,. Enhancing the cytotoxic activity of novel targeted therapiesâIs there a role for a combinatorial approach? Curr Clin Pharmacol 2008; 3: 108-117.
24. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH,. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006; 66: 4816-4825.
25. Minelli A, Bellezza I, Tucci A, Conte C, Bracarda S, Culig Z,. 2-Chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells. Prostate 2008; 68: 360-372. (Pubitemid 351342642)
26. Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T, Tomita Y,. Glycogen synthase kinase-3: A new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101: 2005-2014.
27. Elsea CR, Roberts DA, Druker BJ, Wood LJ,. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS ONE 2008; 3: e2355.
28. Xiao D, Singh SV,. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62: 3615-3619. (Pubitemid 34728834)
29. Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM,. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urol Oncol 2010 (in press).
30. Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Gul MK, Erten C, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA, Uslu R,. Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 2010; 37: 1269-1277.
31. Karabulut B, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C, Uslu R,. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines. Mol Biol Rep 2011; 38: 249-259.
32. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB,. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56-63. (Pubitemid 40410468)
33. Fernandez A, Udagawa T, Schwesinger C, Beecken WD, Chilles-Gerte E, McDonnell TJ, D'Amato RJ,. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213. (Pubitemid 32166491)
34. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E,. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-669.
35. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace AJ,. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18: 6845-6854.
36. Salnikow K, Costa M, Figg WD, Blagosklonny MV,. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 2000; 60: 5630-5634.
37. Benninghoff J, Kartarius S, Teleb Z, Selter H, Unteregger G, Zwergel T, Wullich B, Montenarh M,. Two different forms of p53 localized differently within cells of urogenital tumours. Cancer Lett 1999; 144: 55-64. (Pubitemid 29392898)
38. Wee KB, Surana U, Aguda BD,. Oscillations of the p53-Akt network: Implications on cell survival and death. PLoS ONE 2009; 4: e4407.
39. Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, Schofield AC,. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res 2004; 6: R601-R607.
40. Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB,. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635-6640.
41. Fernando RI, Wimalasena J,. Phospho BAD decreases breast cancer cell proliferation by inhibiting c-jun activation of the CRE in cyclin D1. AACR Meeting Abstr 2005; 2005: 1279.
42. Jiang P, Du W, Wu M,. p53 and Bad: Remote strangers become close friends. Cell Res 2007; 17: 283-285. (Pubitemid 46639925)